Cargando…

Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma

Glioblastoma is a lethal primary brain tumor lacking effective therapy. The secluded onset site, combined with the infiltrative properties of this tumor, require novel targeted therapies. In this scenario, the use of oncolytic viruses retargeted to glioblastoma cells and able to spread across the tu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Appolloni, Irene, Alessandrini, Francesco, Menotti, Laura, Avitabile, Elisa, Marubbi, Daniela, Piga, Noemi, Ceresa, Davide, Piaggio, Francesca, Campadelli-Fiume, Gabriella, Malatesta, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473268/ https://www.ncbi.nlm.nih.gov/pubmed/34578259 http://dx.doi.org/10.3390/v13091677

Ejemplares similares

HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses
por: Menotti, Laura, et al.
Publicado: (2018)

Retargeting Strategies for Oncolytic Herpes Simplex Viruses
por: Campadelli-Fiume, Gabriella, et al.
Publicado: (2016)

Point Mutations in Retargeted gD Eliminate the Sensitivity of EGFR/EGFRvIII-Targeted HSV to Key Neutralizing Antibodies
por: Tuzmen, Ceren, et al.
Publicado: (2020)

Efficacy of Systemically Administered Retargeted Oncolytic Herpes Simplex Viruses—Clearance and Biodistribution in Naïve and HSV-Preimmune Mice
por: Vannini, Andrea, et al.
Publicado: (2023)

Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers
por: Vannini, Andrea, et al.
Publicado: (2023)

Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases
por: Leoni, Valerio, et al.
Publicado: (2015)

EGFRvIII: the promiscuous mutation
por: Greenall, Sameer A, et al.
Publicado: (2016)

Noninvasive Monitoring of Glioma Growth in the Mouse
por: Alessandrini, Francesco, et al.
Publicado: (2016)

A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors
por: Leoni, Valerio, et al.
Publicado: (2018)

A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells
por: Leoni, Valerio, et al.
Publicado: (2017)

Efficacy of osimertinib against EGFRvIII+ glioblastoma
por: Chagoya, Gustavo, et al.
Publicado: (2020)

Retargeted human avidin-CAR T cells for adoptive immunotherapy of EGFRvIII expressing gliomas and their evaluation via optical imaging
por: Liu, Kaiyu, et al.
Publicado: (2015)

Insertion of a ligand to HER2 in gB retargets HSV tropism and obviates the need for activation of the other entry glycoproteins
por: Petrovic, Biljana, et al.
Publicado: (2017)

Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII(+)PTEN(−) glioblastoma in vivo
por: Xu, Wen, et al.
Publicado: (2016)

Cdh4 Down-Regulation Impairs in Vivo Infiltration and Malignancy in Patients Derived Glioblastoma Cells
por: Ceresa, Davide, et al.
Publicado: (2019)

The natural history of EGFR and EGFRvIII in glioblastoma patients
por: Heimberger, Amy B, et al.
Publicado: (2005)

Targeting FHL2 for EGFRvIII-positive glioblastoma
por: Sun, Lili, et al.
Publicado: (2018)

Towards a Precision Medicine Approach and In Situ Vaccination against Prostate Cancer by PSMA-Retargeted oHSV
por: Vannini, Andrea, et al.
Publicado: (2021)

Simultaneous Insertion of Two Ligands in gD for Cultivation of Oncolytic Herpes Simplex Viruses in Noncancer Cells and Retargeting to Cancer Receptors
por: Leoni, Valerio, et al.
Publicado: (2018)

Development of an EGFRvIII specific recombinant antibody
por: Gupta, Puja, et al.
Publicado: (2010)

Preclinical Therapy of Disseminated HER-2(+) Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus
por: Nanni, Patrizia, et al.
Publicado: (2013)

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma
por: Padfield, Emily, et al.
Publicado: (2015)

The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis
por: Hoogstrate, Youri, et al.
Publicado: (2021)

Genotype of Immunologically Hot or Cold Tumors Determines the Antitumor Immune Response and Efficacy by Fully Virulent Retargeted oHSV
por: Gianni, Tatiana, et al.
Publicado: (2021)

Phenotypical Flexibility of the EGFRvIII-Positive Glioblastoma Cell Line and the Multidirectional Influence of TGFβ and EGF on These Cells—EGFRvIII Appears as a Weak Oncogene
por: Włodarczyk, Aneta, et al.
Publicado: (2022)

Will EGFRvIII and neuronal-derived EGFR be targets for imipramine?
por: Li, Zesheng, et al.
Publicado: (2023)

Synergistic antitumor efficacy against the EGFRvIII(+)HER2(+) breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12
por: Xu, Wen, et al.
Publicado: (2015)

EGFRvIII Is Expressed in Cellular Areas of Tumor in a Subset of Glioblastoma
por: NOZAWA, Takanori, et al.
Publicado: (2019)

GZ17-6.02 Inhibits the Growth of EGFRvIII+ Glioblastoma
por: Choi, Justin, et al.
Publicado: (2022)

Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells
por: Petrovic, Biljana, et al.
Publicado: (2018)

Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma
por: Sahin, Ayguen, et al.
Publicado: (2018)

EGFRvIII expression and isocitrate dehydrogenase mutations in patients with glioma
por: Taher, Mohiuddin M., et al.
Publicado: (2020)

Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody
por: Choi, Bryan D, et al.
Publicado: (2013)

EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells
por: Struve, Nina, et al.
Publicado: (2015)

Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma
por: Velpula, Kiran K., et al.
Publicado: (2017)

Challenges in EGFRvIII Detection in Head and Neck Squamous Cell Carcinoma
por: Wheeler, Sarah E., et al.
Publicado: (2015)

A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII
por: Trembath, Dimitri G, et al.
Publicado: (2007)

Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma
por: Babu, Ranjith, et al.
Publicado: (2012)

Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition
por: Shen, Ying, et al.
Publicado: (2015)

Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme
por: Newman, Jennifer P., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_i0jmdrtnmjp8gatb4kgv9svp6v